SAA2 and COVID-19: By performing proteomic and metabolomic profiling of sera from COVID‐19 patients and healthy individuals, Shen et al. (2020) found a remarkable elevation of serum amyloid A1 (SAA1), SAA2, SAA4, and other inflammation markers (e.g., C‐reactive protein, SAP, and SERPINA3) in severe COVID‐19 patients compared to non‐severe COVID‐19 patients and healthy individuals.